Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2025 Filed May 20, 2025 17:56 UTC |
Menawat Arun SwarupDirector · CEO
|
PurchaseCommon Shares | 12,027 | $4.73 | $56,887.71 |
DisclosureSEC source: 0001171843-25-003336 · ownership.xml · nonDerivative · entry 2 Menawat Arun Swarup · CIK 0001685893 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,089 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 15, 2025 Filed May 20, 2025 17:56 UTC |
Menawat Arun SwarupDirector · CEO
|
PurchaseCommon Shares | 10,003 | $4.33 | $43,262.98 |
DisclosureSEC source: 0001171843-25-003336 · ownership.xml · nonDerivative · entry 1 Menawat Arun Swarup · CIK 0001685893 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,062 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.